Search

Bio-Techne Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

71.93 0.39

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

71.51

Max

71.83

Pagrindiniai rodikliai

By Trading Economics

Pajamos

13M

51M

Pardavimai

16M

311M

P/E

Sektoriaus vid.

103.826

62.58

Pelnas, tenkantis vienai akcijai

0.53

Dividendų pajamingumas

0.44

Pelno marža

16.392

Darbuotojai

3,100

EBITDA

21M

99M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-6.34% downside

Dividendai

By Acuity

Dividendų pajamingumas

Sektoriaus vid.

0.44%

2.19%

Kitas uždarbis

2026-08-05

Kitas dividendų mokėjimo data

2026-08-28

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

2.6B

11B

Ankstesnė atidarymo kaina

71.54

Ankstesnė uždarymo kaina

71.93

Naujienos nuotaikos

By Acuity

65%

35%

296 / 340 reitingas Healthcare

Bio-Techne Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-20 18:01; UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Akcijų palyginimas

Kainos pokytis

Bio-Techne Corp Prognozė

Kainos tikslas

By TipRanks

-6.34% į apačią

12 mėnesių prognozė

Vidutinis 67.09 USD  -6.34%

Aukščiausias 73 USD

Žemiausias 50 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Bio-Techne Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

14 ratings

1

Pirkti

13

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

296 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat